Suppr超能文献

支持心脏变时性β2肾上腺素能受体。

In support of cardiac chronotropic beta 2 adrenoceptors.

作者信息

Brown J E, McLeod A A, Shand D G

出版信息

Am J Cardiol. 1986 Apr 25;57(12):11F-16F. doi: 10.1016/0002-9149(86)90882-9.

Abstract

The effects of atenolol (50 mg) and propranolol (40 mg) on exercise- and isoproterenol-induced heart rate increments were studied in 9 male volunteers. Propranolol reduced maximal heart rate from 187 +/- 4 to 146 +/- 7 beats/min and atenolol reduced it to 138 +/- 6 beats/min. There was no difference between the drugs at any point during exercise. Isoproterenol sensitivity was measured as the dose of isoproterenol required to increase resting heart rate by 25 beats/min (CD-25). Propranolol increased the CD-25 from 1.8 +/- 0.3 micrograms after placebo to 39 +/- 8 micrograms and atenolol increased the CD-25 to 8 +/- 2 micrograms. The increase by propranolol was significantly greater than that of atenolol. Intravenous atropine (0.04 mg/kg) did not alter the isoproterenol CD-25 during placebo or atenolol. The CD-25 with propranolol decreased after atropine (39 +/- 8 versus 25 +/- 5 micrograms) and was due to diminished plasma propranolol concentrations as the drug sensitivity (measured by Ka) was unchanged before (12 +/- 2 ml/ng) and after (10 +/- 3 ml/ng) atropine. These data support the hypothesis that moderate exercise is primarily a beta 1-mediated response and therefore equally antagonized by cardioselective and nonselective blockers, but that isoproterenol stimulates both beta 1 and beta 2 receptors. The greater ability of the nonselective agent to antagonize isoproterenol tachycardia with no significant change after atropine suggests the presence of cardiac beta 2 chronotropic receptors. The physiologic and pathologic importance of these receptors has yet to be determined.

摘要

在9名男性志愿者中研究了阿替洛尔(50毫克)和普萘洛尔(40毫克)对运动及异丙肾上腺素诱导的心率增加的影响。普萘洛尔使最大心率从187±4次/分钟降至146±7次/分钟,阿替洛尔则将其降至138±6次/分钟。运动过程中任何时间点两种药物之间均无差异。异丙肾上腺素敏感性通过使静息心率增加25次/分钟所需的异丙肾上腺素剂量(CD-25)来衡量。普萘洛尔使CD-25从安慰剂后的1.8±0.3微克增加至39±8微克,阿替洛尔使CD-25增加至8±2微克。普萘洛尔的增加显著大于阿替洛尔。静脉注射阿托品(0.04毫克/千克)在安慰剂或阿替洛尔期间未改变异丙肾上腺素CD-25。使用普萘洛尔时,阿托品后CD-25降低(39±8微克对25±5微克),这是由于血浆普萘洛尔浓度降低,因为药物敏感性(通过Ka测量)在阿托品前(12±2毫升/纳克)和后(10±3毫升/纳克)未改变。这些数据支持以下假设:适度运动主要是β1介导的反应,因此心脏选择性和非选择性阻滞剂均可同等拮抗,但异丙肾上腺素刺激β1和β2受体。非选择性药物拮抗异丙肾上腺素性心动过速的能力更强,且阿托品后无显著变化,提示存在心脏β2变时性受体。这些受体的生理和病理重要性尚未确定。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验